These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 31715018)
1. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels. Yoon DY; Lee S; Ban MS; Jang IJ; Lee S Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802 [TBL] [Abstract][Full Text] [Related]
3. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data. Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view. Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752 [TBL] [Abstract][Full Text] [Related]
5. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines. Pritchard D; Patel JN; Stephens LE; McLeod HL Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418 [TBL] [Abstract][Full Text] [Related]
6. ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels. Deb S; Hopefl R; Reeves AA; Cvetkovic D Medicines (Basel); 2024 Feb; 11(3):. PubMed ID: 38535119 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Abdullah-Koolmees H; van Keulen AM; Nijenhuis M; Deneer VHM Front Pharmacol; 2020; 11():595219. PubMed ID: 33568995 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic biomarker information on drug labels of the Spanish Agency of Medicines and Sanitary products: evaluation and comparison with other regulatory agencies. Estévez-Paredes M; Mata-Martín MC; de Andrés F; LLerena A Pharmacogenomics J; 2024 Jan; 24(1):2. PubMed ID: 38233388 [TBL] [Abstract][Full Text] [Related]
12. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies. Nagy M; Attya M; Patrinos GP Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490 [TBL] [Abstract][Full Text] [Related]
13. Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Koutsilieri S; Tzioufa F; Sismanoglou DC; Patrinos GP Pharmacol Res; 2020 Mar; 153():104590. PubMed ID: 31830522 [TBL] [Abstract][Full Text] [Related]
14. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics. Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061 [TBL] [Abstract][Full Text] [Related]
15. Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Tsukagoshi E; Tanaka Y; Saito Y Front Med (Lausanne); 2021; 8():644154. PubMed ID: 33842507 [TBL] [Abstract][Full Text] [Related]
16. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016). Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels. Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics: history, barriers, and regulatory solutions. Blankstein S Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016 [TBL] [Abstract][Full Text] [Related]